We currently have a vacancy for a pharmaceutical assessor to join the Defective Medicines Report Centre (DMRC) team, working closely with the Inspectorate as part of the Inspection Enforcement and Standards Division of the MHRA.
Sandra is Manager of the Defective Medicines report Centre at the MHRA. She is a Chartered Chemist and a Qualified Person, with a MSc in Industrial Pharmaceutical Studies, and has over thirty years’ experience in the pharmaceutical industry. She has worked in large multi-nationals, as well as medium and small start up companies. As a QP, Sandra has expertise in GMP and pharmaceutical quality systems. Through her earlier roles in R&D Analytical Development she gained knowledge of stability testing of formulated products and active substances, and in New Product Introduction was involved in cleaning validation and technology transfer.
Following on from the previous DMRC overview post, here are some Do’s (What, When & How) for reporting defects to the DMRC, and also some Don'ts to avoid.
Joiners and leavers Those of you that have contacted the Defective Medicines Report Centre (DMRC) recently may have encountered some new names – I started as manager of the DMRC team in early April, joining Christine Cox and Alison Bunce. Also …
Related content and links
About the MHRA Inspectorate Blog
This blog shares the work of the Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate, by inspectors and those the Inspectorate works with.
Other MHRA Blogs
Comments and moderation
- Compliance Monitor Process (Part 2)– CM role and application process
- Compliance Monitor process (Part 1) – An introduction
- MHRA Good Practice Symposia Week (7 to 11 March 2022)
- Regulators’ experience of clinical trials during the Covid-19 pandemic (Part 3) – looking forward
- Regulator’s experience of clinical trials during the Covid-19 pandemic (Part 2) – what we have learned